Albireo to Present at 2020 Jefferies Virtual Healthcare Conference
26 Mai 2020 - 2:00PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that Ron Cooper, President and Chief
Executive Officer, will present via webcast at the 2020 Jefferies
Virtual Healthcare Conference on Tuesday, June 2, at 8:30 a.m. EDT.
The live webcast of the presentation will be accessible from the
Media & Investors page of Albireo’s
website, ir.albireopharma.com. To ensure a timely connection
to the webcast, it is recommended that users register at least 15
minutes prior to the scheduled start time. An archived version of
the webcast will be available for replay in the Events &
Presentations section of the Media & Investors page of
Albireo’s website for at least two weeks following the event.
About AlbireoAlbireo Pharma is a clinical-stage
biopharmaceutical company focused on the development of novel bile
acid modulators to treat orphan pediatric liver diseases, and other
liver and gastrointestinal diseases and disorders. Albireo’s lead
product candidate, odevixibat, is being developed to treat rare
pediatric cholestatic liver diseases and is in Phase 3 development
in progressive familial intrahepatic cholestasis (PFIC) and biliary
atresia. Albireo’s clinical pipeline also includes two Phase 2
product candidates. Elobixibat is in Phase 2 development in NAFLD
and NASH. Approved in Japan for the treatment of chronic
constipation, elobixibat is the first ileal bile acid transporter
(IBAT) inhibitor approved anywhere in the world.
Albireo was spun out from AstraZeneca in
2008. Albireo Pharma is located in Boston, Mass.,
and its key operating subsidiary is located in Gothenburg,
Sweden. The Boston Business Journal named Albireo one of
the 2019 Best Places to Work in Massachusetts. For more
information on Albireo, please
visit www.albireopharma.com.
Investor Contact: Hans Vitzthum, LifeSci
Advisors, LLC, 617-430-7578Media Contact: Claire
LaCagnina, 6 Degrees, 315-765-1462, clacagnina@6degreespr.com
Source: Albireo Pharma, Inc.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024